Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring.

Fink DL, Bloch E.

Int J STD AIDS. 2013 Oct;24(10):831-3. doi: 10.1177/0956462413483720. Epub 2013 Jul 19.

PMID:
23970595
2.

A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.

Turkova A, Ball C, Gilmour-White S, Rela M, Mieli-Vergani G.

J Antimicrob Chemother. 2009 Mar;63(3):623-5. doi: 10.1093/jac/dkn548. Epub 2009 Jan 22. No abstract available.

PMID:
19164417
3.

Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.

Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET.

Afr Health Sci. 2011 Mar;11(1):16-23.

5.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, MarĂ­n A, Hernandez-Ranz F, Moreno A, Moreno S.

Clin Infect Dis. 2005 Feb 15;40(4):588-93. Epub 2005 Jan 21.

PMID:
15712082
6.

Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.

Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S; TREAT Asia HIV Observational Database.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):501-3. No abstract available.

PMID:
17099317
7.

[Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)].

Vennarecci G, Ettorre GM, Antonini M, Maritti M, Moricca P, D'Offizzi G, Narciso P, Lonardo MT, Boschetto A, Del Nonno F, Perracchio L, Palmieri GP, Visco G, Santoro E.

Tumori. 2003 Jul-Aug;89(4 Suppl):159-61. Italian.

PMID:
12903579
8.

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.

Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, Hudson M, Masson S.

J Clin Virol. 2013 Sep;58(1):331-3. doi: 10.1016/j.jcv.2013.05.003. Epub 2013 Jun 12.

PMID:
23763943
9.

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA.

AIDS. 2003 Oct 17;17(15):2191-9.

PMID:
14523276
10.

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G; EPOKA-MASTER Study Group.

BMC Infect Dis. 2005 Jul 14;5:58.

11.

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.

Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G.

PLoS One. 2010 Feb 17;5(2):e9183. doi: 10.1371/journal.pone.0009183.

12.

Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.

Sogbanmu OO, Adeniyi OV, Fuentes YO, Ter Goon D.

J Med Case Rep. 2015 May 7;9:106. doi: 10.1186/s13256-015-0557-0.

13.

Does tenofovir increase efavirenz hepatotoxicity?

Lattuada E, Lanzafame M, Carolo G, Gottardi M, Concia E, Vento S.

AIDS. 2008 May 11;22(8):995. doi: 10.1097/QAD.0b013e3282fc27c4. No abstract available.

PMID:
18453862
14.
15.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

Hepatology. 2002 Jan;35(1):182-9.

PMID:
11786975
16.

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.

Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022. Epub 2013 Nov 25.

PMID:
24359841
17.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
19.

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G.

JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530.

PMID:
18677025
20.

[Liver transplantation in a HIV-positive patient receiving potent antiretroviral therapy; the first case in The Netherlands].

Honkoop P, Kazemier G, Perenboom RM, van de Ende ME, de Man RA.

Ned Tijdschr Geneeskd. 2004 Dec 11;148(50):2500-4. Dutch.

PMID:
15638199

Supplemental Content

Support Center